339 related articles for article (PubMed ID: 19843069)
1. Fibroblast growth factor receptor 3 mutation in voided urine is a useful diagnostic marker and significant indicator of tumor recurrence in non-muscle invasive bladder cancer.
Miyake M; Sugano K; Sugino H; Imai K; Matsumoto E; Maeda K; Fukuzono S; Ichikawa H; Kawashima K; Hirabayashi K; Kodama T; Fujimoto H; Kakizoe T; Kanai Y; Fujimoto K; Hirao Y
Cancer Sci; 2010 Jan; 101(1):250-8. PubMed ID: 19843069
[TBL] [Abstract][Full Text] [Related]
2. Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle-invasive bladder cancer.
Zuiverloon TC; van der Aa MN; van der Kwast TH; Steyerberg EW; Lingsma HF; Bangma CH; Zwarthoff EC
Clin Cancer Res; 2010 Jun; 16(11):3011-8. PubMed ID: 20404005
[TBL] [Abstract][Full Text] [Related]
3. Optimization of nonmuscle invasive bladder cancer recurrence detection using a urine based FGFR3 mutation assay.
Zuiverloon TC; Tjin SS; Busstra M; Bangma CH; Boevé ER; Zwarthoff EC
J Urol; 2011 Aug; 186(2):707-12. PubMed ID: 21683397
[TBL] [Abstract][Full Text] [Related]
4. The development of multiple bladder tumour recurrences in relation to the FGFR3 mutation status of the primary tumour.
Kompier LC; van der Aa MN; Lurkin I; Vermeij M; Kirkels WJ; Bangma CH; van der Kwast TH; Zwarthoff EC
J Pathol; 2009 May; 218(1):104-12. PubMed ID: 19156776
[TBL] [Abstract][Full Text] [Related]
5. A 3-plex methylation assay combined with the FGFR3 mutation assay sensitively detects recurrent bladder cancer in voided urine.
Kandimalla R; Masius R; Beukers W; Bangma CH; Orntoft TF; Dyrskjot L; van Leeuwen N; Lingsma H; van Tilborg AA; Zwarthoff EC
Clin Cancer Res; 2013 Sep; 19(17):4760-9. PubMed ID: 23842048
[TBL] [Abstract][Full Text] [Related]
6. Identification of fibroblast growth factor receptor 3 mutations in urine sediment DNA samples complements cytology in bladder tumor detection.
Rieger-Christ KM; Mourtzinos A; Lee PJ; Zagha RM; Cain J; Silverman M; Libertino JA; Summerhayes IC
Cancer; 2003 Aug; 98(4):737-44. PubMed ID: 12910517
[TBL] [Abstract][Full Text] [Related]
7. A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine.
van Oers JM; Lurkin I; van Exsel AJ; Nijsen Y; van Rhijn BW; van der Aa MN; Zwarthoff EC
Clin Cancer Res; 2005 Nov; 11(21):7743-8. PubMed ID: 16278395
[TBL] [Abstract][Full Text] [Related]
8. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate.
van Rhijn BW; Lurkin I; Radvanyi F; Kirkels WJ; van der Kwast TH; Zwarthoff EC
Cancer Res; 2001 Feb; 61(4):1265-8. PubMed ID: 11245416
[TBL] [Abstract][Full Text] [Related]
9. Sensitive detection of FGFR3 mutations in bladder cancer and urine sediments by peptide nucleic acid-mediated real-time PCR clamping.
Miyake M; Sugano K; Kawashima K; Ichikawa H; Hirabayashi K; Kodama T; Fujimoto H; Kakizoe T; Kanai Y; Fujimoto K; Hirao Y
Biochem Biophys Res Commun; 2007 Nov; 362(4):865-71. PubMed ID: 17803960
[TBL] [Abstract][Full Text] [Related]
10. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome.
van Rhijn BW; Vis AN; van der Kwast TH; Kirkels WJ; Radvanyi F; Ooms EC; Chopin DK; Boevé ER; Jöbsis AC; Zwarthoff EC
J Clin Oncol; 2003 May; 21(10):1912-21. PubMed ID: 12743143
[TBL] [Abstract][Full Text] [Related]
11. CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma.
Rebouissou S; Hérault A; Letouzé E; Neuzillet Y; Laplanche A; Ofualuka K; Maillé P; Leroy K; Riou A; Lepage ML; Vordos D; de la Taille A; Denoux Y; Sibony M; Guyon F; Lebret T; Benhamou S; Allory Y; Radvanyi F
J Pathol; 2012 Jul; 227(3):315-24. PubMed ID: 22422578
[TBL] [Abstract][Full Text] [Related]
12. PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors.
Dueñas M; Martínez-Fernández M; García-Escudero R; Villacampa F; Marqués M; Saiz-Ladera C; Duarte J; Martínez V; Gómez MJ; Martín ML; Fernández M; Castellano D; Real FX; Rodriguez-Peralto JL; De La Rosa F; Paramio JM
Mol Carcinog; 2015 Jul; 54(7):566-76. PubMed ID: 24347284
[TBL] [Abstract][Full Text] [Related]
13. [Correlation of FGFR3 mutations and chromosomal alterations in bladder cancer].
Junker K; van Oers JM; Zwarthoff EC; Kania I; Schubert J; Hartmann A
Verh Dtsch Ges Pathol; 2006; 90():151-8. PubMed ID: 17867592
[TBL] [Abstract][Full Text] [Related]
14. Combined microsatellite and FGFR3 mutation analysis enables a highly sensitive detection of urothelial cell carcinoma in voided urine.
van Rhijn BW; Lurkin I; Chopin DK; Kirkels WJ; Thiery JP; van der Kwast TH; Radvanyi F; Zwarthoff EC
Clin Cancer Res; 2003 Jan; 9(1):257-63. PubMed ID: 12538478
[TBL] [Abstract][Full Text] [Related]
15. Mutations of fibroblast growth factor receptor 3 gene (FGFR3) in transitional cell carcinoma of urinary bladder in Thai patients [Revision-2a].
Jantip J; Tanthanuch M; Kanngurn S; Karnchanawanichkul W; Pripatnanont C; Sangkhathat S; Thongsuksai P
J Med Assoc Thai; 2013 Aug; 96(8):976-83. PubMed ID: 23991606
[TBL] [Abstract][Full Text] [Related]
16. FGFR3 mutation analysis in voided urine samples to decrease cystoscopies and cost in nonmuscle invasive bladder cancer surveillance: a comparison of 3 strategies.
van Kessel KE; Kompier LC; de Bekker-Grob EW; Zuiverloon TC; Vergouwe Y; Zwarthoff EC; Steyerberg EW
J Urol; 2013 May; 189(5):1676-81. PubMed ID: 23142690
[TBL] [Abstract][Full Text] [Related]
17. Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer.
Roperch JP; Grandchamp B; Desgrandchamps F; Mongiat-Artus P; Ravery V; Ouzaid I; Roupret M; Phe V; Ciofu C; Tubach F; Cussenot O; Incitti R
BMC Cancer; 2016 Sep; 16(1):704. PubMed ID: 27586786
[TBL] [Abstract][Full Text] [Related]
18. The Diagnostic and Prognostic Performance of Urinary FGFR3 Mutation Analysis in Bladder Cancer Surveillance: A Prospective Multicenter Study.
Couffignal C; Desgrandchamps F; Mongiat-Artus P; Ravery V; Ouzaid I; Roupret M; Phe V; Ciofu C; Tubach F; Mentre F; Cussenot O; Grandchamp B
Urology; 2015 Dec; 86(6):1185-90. PubMed ID: 26364695
[TBL] [Abstract][Full Text] [Related]
19. Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors.
Zieger K; Dyrskjøt L; Wiuf C; Jensen JL; Andersen CL; Jensen KM; Ørntoft TF
Clin Cancer Res; 2005 Nov; 11(21):7709-19. PubMed ID: 16278391
[TBL] [Abstract][Full Text] [Related]
20. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas.
Hernández S; López-Knowles E; Lloreta J; Kogevinas M; Amorós A; Tardón A; Carrato A; Serra C; Malats N; Real FX
J Clin Oncol; 2006 Aug; 24(22):3664-71. PubMed ID: 16877735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]